JP2023535073A5 - - Google Patents
Info
- Publication number
- JP2023535073A5 JP2023535073A5 JP2023504634A JP2023504634A JP2023535073A5 JP 2023535073 A5 JP2023535073 A5 JP 2023535073A5 JP 2023504634 A JP2023504634 A JP 2023504634A JP 2023504634 A JP2023504634 A JP 2023504634A JP 2023535073 A5 JP2023535073 A5 JP 2023535073A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055777P | 2020-07-23 | 2020-07-23 | |
| US63/055,777 | 2020-07-23 | ||
| US202063069077P | 2020-08-23 | 2020-08-23 | |
| US63/069,077 | 2020-08-23 | ||
| US202163143829P | 2021-01-30 | 2021-01-30 | |
| US63/143,829 | 2021-01-30 | ||
| PCT/US2021/040998 WO2022020107A1 (en) | 2020-07-23 | 2021-07-09 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023535073A JP2023535073A (ja) | 2023-08-15 |
| JP2023535073A5 true JP2023535073A5 (https=) | 2024-07-18 |
| JPWO2022020107A5 JPWO2022020107A5 (https=) | 2024-07-18 |
| JP7803926B2 JP7803926B2 (ja) | 2026-01-21 |
Family
ID=79728346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504634A Active JP7803926B2 (ja) | 2020-07-23 | 2021-07-09 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230285586A1 (https=) |
| EP (1) | EP4185330A4 (https=) |
| JP (1) | JP7803926B2 (https=) |
| KR (1) | KR20230044242A (https=) |
| CN (1) | CN116368150A (https=) |
| AU (1) | AU2021312709A1 (https=) |
| BR (1) | BR112023001125A2 (https=) |
| CA (1) | CA3186752A1 (https=) |
| IL (1) | IL299662A (https=) |
| MX (1) | MX2023000984A (https=) |
| WO (1) | WO2022020107A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12497615B2 (en) | 2019-04-25 | 2025-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| WO2022020108A1 (en) * | 2020-07-23 | 2022-01-27 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| US20240100177A1 (en) * | 2020-12-04 | 2024-03-28 | Dyne Therapeutics, Inc. | Antibody-oligonucleotide complexes and uses thereof |
| WO2022270585A1 (ja) | 2021-06-23 | 2022-12-29 | 日本新薬株式会社 | アンチセンスオリゴマーの組み合わせ |
| IL309936A (en) * | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP4366783A4 (en) * | 2021-07-09 | 2025-08-27 | Dyne Therapeutics Inc | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF DYSTROPHINOPATHIES |
| CA3226300A1 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| MX2024000490A (es) * | 2021-07-09 | 2024-04-10 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para tratar las distrofinopatías. |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| KR20240032945A (ko) * | 2021-07-09 | 2024-03-12 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| WO2024226471A2 (en) | 2023-04-24 | 2024-10-31 | Biomarin Pharmaceutical Inc. | Compositions and methods for treating stxbp1 disorders |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130164A2 (en) * | 2010-04-13 | 2011-10-20 | The Regents Of The University Of California | Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer |
| PE20141114A1 (es) * | 2010-12-20 | 2014-09-15 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| PT3097122T (pt) * | 2014-01-24 | 2020-07-21 | Ngm Biopharmaceuticals Inc | Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos |
| TWI769982B (zh) * | 2015-06-24 | 2022-07-11 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之抗人類運鐵蛋白受體抗體 |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| US20200282074A1 (en) * | 2017-09-22 | 2020-09-10 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| AR126019A1 (es) * | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| EP3829595A4 (en) * | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| WO2020028842A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy |
| GB2595980B (en) * | 2019-01-04 | 2023-06-14 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| JP7780691B2 (ja) * | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| CN116348138A (zh) * | 2020-07-23 | 2023-06-27 | 达因疗法公司 | 抗转铁蛋白受体（tfr）抗体及其用途 |
| WO2022020108A1 (en) * | 2020-07-23 | 2022-01-27 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
-
2021
- 2021-07-09 KR KR1020237005853A patent/KR20230044242A/ko active Pending
- 2021-07-09 WO PCT/US2021/040998 patent/WO2022020107A1/en not_active Ceased
- 2021-07-09 AU AU2021312709A patent/AU2021312709A1/en active Pending
- 2021-07-09 EP EP21846687.8A patent/EP4185330A4/en active Pending
- 2021-07-09 JP JP2023504634A patent/JP7803926B2/ja active Active
- 2021-07-09 BR BR112023001125A patent/BR112023001125A2/pt unknown
- 2021-07-09 CN CN202180064570.5A patent/CN116368150A/zh active Pending
- 2021-07-09 CA CA3186752A patent/CA3186752A1/en active Pending
- 2021-07-09 MX MX2023000984A patent/MX2023000984A/es unknown
- 2021-07-09 IL IL299662A patent/IL299662A/en unknown
- 2021-07-09 US US18/017,179 patent/US20230285586A1/en active Pending